H.C. Wainwright reiterates Buy rating on TuHURA Biosciences stock at $12 target

TuHURA Biosciences (NASDAQ:HURA) has initiated a pivotal Phase 3 trial for its lead innate immune agonist, IFx-2.0, as an adjunctive therapy with Keytruda in advanced or metastatic Merkel cell carcinoma. This trial, operating under an FDA Special Protocol Assessment and targeting Objective Response Rate for potential accelerated approval, has led H.C. Wainwright to reiterate its Buy rating and $12.00 price target, indicating substantial upside from its current price. The company's strategic positioning is further bolstered by the recent lifting of a clinical hold and an impending merger with Kineta, despite recent stock declines and noted rapid cash consumption.

Analysis

TuHURA Biosciences has reached a significant clinical milestone with the initiation of its pivotal Phase 3 trial for its lead candidate, IFx-2.0, in Merkel cell carcinoma. The trial's design as an adjunctive therapy with Keytruda, operating under a Special Protocol Assessment (SPA) with the FDA, suggests a well-defined regulatory path toward potential accelerated approval based on the primary endpoint of objective response rate. This progress substantiates H.C. Wainwright's reiterated Buy rating and $12.00 price target, which, alongside other analyst targets ranging from $9.25 to $15.00, implies substantial upside from the current $2.22 stock price. Financially, the company's $97M market capitalization is supported by a healthy current ratio of 3.0, but this is critically tempered by a noted rapid cash consumption, a key risk for a clinical-stage biotech. Additional positive developments include the recent lifting of an FDA partial clinical hold, which triggered a $2.23 million payment, and an impending merger with Kineta set to broaden its pipeline. Despite this positive news flow, the stock's recent 12.25% decline indicates a potential dislocation between fundamental progress and current market valuation.

Key Decisions for Investors

• For investors with a high risk tolerance, the significant disconnect between the current share price of $2.22 and the analyst price target range of $9.25-$15.00 may present a speculative opportunity, given the de-risked regulatory pathway via the FDA's Special Protocol Assessment.
• It is crucial to closely monitor the company's cash burn rate and liquidity, as the reported rapid cash consumption represents a material risk that could necessitate dilutive financing before trial completion.
• Investors should track key near-term catalysts, including the finalization of the Kineta merger, enrollment progress in the 118-patient Phase 3 trial, and any interim data readouts on the primary endpoint of Objective Response Rate.